Sign In
Buy GLMD
$0.680
-0.0111 (-1.61%)
At Close: Jun 03, 2026
- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conve
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidifi
Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Is
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update
02:38am, Saturday, 25'th Apr 2026
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 502,390 s
Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleino
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
11:04am, Thursday, 09'th Apr 2026
Galmed said it developed a new formulation of its SCD1 inhibitor, Aramchol, designed to cross the blood-brain barrier and target central nervous system diseases.
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
07:30am, Thursday, 09'th Apr 2026
98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcod
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
04:15pm, Tuesday, 31'st Mar 2026
TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases
Surrozen (NASDAQ:SRZN) & Galmed Pharmaceuticals (NASDAQ:GLMD) Financial Review
01:28am, Saturday, 14'th Feb 2026
Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two b
Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Decreases By 15.8%
01:43am, Monday, 02'nd Feb 2026
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
04:15pm, Friday, 30'th Jan 2026
TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases a
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
08:30am, Monday, 08'th Dec 2025
Late Breaking Abstract titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramcho
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
08:30am, Thursday, 04'th Dec 2025
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in th
Galmed Issues CEO Letter to Shareholders
08:30am, Monday, 01'st Dec 2025
TEL AVIV, Israel , Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, an
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
08:30am, Wednesday, 26'th Nov 2025
TEL AVIV, Israel , Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, a
